-
Scientists discover antibodies capable of stopping several coronaviruses, potentially preventing future outbreaks
Medical Mythbusting Commentary for July 31, 2023 Source:Scientists discover antibodies capable of stopping several coronaviruses, potentially preventing future outbreaks Reference:Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor
-
Small in vitro study suggests two new COVID subvariants may dodge natural immunity response. However whether this translates into worsening clinical outcomes remains unanswered.
Medical Mythbusting Commentary for May 4, 2022 Source:Two new subvariants of COVID appear to dodge natural immunity Reference: Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing immunity
-
We are not seeing ‘waning immunity’ in fully vaccinated people to date. Some require the 3rd dose specific medical or medication reasons. The intricacies of our immune system are astounding and fascinating. #vaccineswork
Medical Mythbusting Commentary for September 14, 2021 Source:What We Actually Know About Waning Immunity
-
Moderna vs Pfizer antibody titre study cannot answer if it leads to differences in cellular immunity, protection against variants, duration, risks of transmission or clinical outcomes. Real world data shows they both work equally well. #vaccineswork
Medical Mythbusting Commentary for September 1, 2021 Source:Moderna Makes Twice as Many Antibodies as Pfizer, Study Says Reference:Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273
-
Pfizer vaccine recipients have lower neutralizing antibodies targeting delta variant up to three months after first dose. Outcome data needed to determine if this translates into less efficacy. Study concludes second dose interval needs to be shortened.
Medical Mythbusting Commentary for June 4, 2021 Source:Pfizer vaccine recipients have lower antibodies targeting Indian variant – studyPfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant Reference:Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
-
NEJM study concludes that time required to determine Moderna’s effect on longevity of antibody, B and T cell response. However, the vaccine works. Worst-case scenario is that we will require a booster.
Medical Mythbusting Commentary for December 24, 2020 Source:The Moderna Vaccine’s Antibodies May Not Last As Long As We Hoped Reference:Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
-
Study reports that people who had mild to moderate #COVID-19 have protective stable antibody levels five months after their infection. This finding and further studies to follow can help with public policy and vaccine development programs.
Medical Mythbusting Commentary for October 30, 2020 Source:Immunity to coronavirus lingers for months, study finds Reference:Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
-
Vulnerable populations to be the focus in a new Canadian COVID-19 antibody study.
Medical Mythbusting Commentary for October 29, 2020 Source:New Canadian antibody study to investigate COVID-19’s spread, why it hits vulnerable
-
It is too soon to draw any conclusions about short/long term immunity based on COVID-19 antibody levels. Many unknown factors remain. Time should help with the answers in future studies.
Medical Mythbusting Commentary for October 14, 2020 Source:Evidence mounts that immunity from COVID-19 antibodies has limits